Agenda

Ensuring access to medicines at affordable prices requires both supply security and support for the domestic pharmaceutical industry. Introducing innovative therapies and adapting EU regulations are key to maintaining competitiveness and market stability. How can innovation be reconciled with affordability and secure pharmaceutical supply chains?